Ann: HERIZON study results to be featured at ESMO Asia Congress, page-4

ASX Announcement
HER-Vaxx HERIZON study results to be featured at ESMO Asia Congress 2022
Sydney, Australia, 7 October 2022: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased
to announce that an abstract regarding the overall survival results from its HER-Vaxx HERIZON study has been accepted
for an oral presentation at the ESMO Asia Congress 2022, being held in Singapore 2-4 December 2022.
The annual event brings together cancer professionals from Asia as well as other regions globally to present and discuss
the latest scientific and clinical advances from across the field of oncology, of relevance at both a global level and
within Asia-Pacific.
The oral presentation and abstract, number 74MO, is titled 'HERIZON Overall Survival Results: A study of IMU-131, a
HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2 Overexpressing
Metastatic or Advanced Gastric/GEJ Cancer'. It will be presented as part of a session on gastrointestinal tumours by
principal investigator Marina Maglakelidze at 1:40pm (SGT) on 4 December 2022.
The HERIZON study was a Phase 2 clinical trial of Imugene's HER-Vaxx technology in Her-2/Neu overexpressing
advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat
tumours that overexpress the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. The
immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER2/neu.
The data and information presented as part of ESMO will be announced following the lifting of the embargo in late
November 2022.
For more about ESMO Asia Congress 2022, please visit: https://www.esmo.org/meetings/esmo-asia-congress-2022